The analysis revealed that the level of MOTS-c peptide expression gradually decreased in further stages of ACC (p = 0.05), especially in stages III and IV of the disease, compared with stage II, but the difference was not statistically significant. The gene discussed is MT-RNR1; the disease is adrenal cortex carcinoma.